ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

IMRX Company Profile and Key Details

NASDAQ : IMRX

Immuneering Corporation

$1.27

0.02+1.60%

At Close 4:00 PM

56.52

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Immuneering Corporation (IMRX) stock surged +1.60%, trading at $1.27 on NASDAQ, up from the previous close of $1.25. The stock opened at $1.30, fluctuating between $1.24 and $1.30 in the recent session.

Stock Snapshot

1.25

Prev. Close

1.3

Open

45.58M

Market Cap

35.89M

Number of Shares

1.24

Day Low

1.3032

Day High

-0.62

P/E Ratio

62.41%

Free Float in %

-2.04

EPS (TTM)

3.09

Book Value

-1.68

Cash Flow per Share

60.73K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 17, 2025	1.30	1.30	1.24	1.27	60.84K
Apr 16, 2025	1.26	1.30	1.23	1.25	65.25K
Apr 15, 2025	1.28	1.38	1.28	1.29	78.58K
Apr 14, 2025	1.32	1.38	1.25	1.30	215.41K
Apr 11, 2025	1.23	1.34	1.23	1.29	140.87K
Apr 10, 2025	1.28	1.28	1.21	1.24	152.55K
Apr 09, 2025	1.24	1.31	1.13	1.29	414.1K
Apr 08, 2025	1.41	1.41	1.23	1.25	159.86K
Apr 07, 2025	1.38	1.45	1.31	1.35	118.62K
Apr 04, 2025	1.47	1.50	1.40	1.41	149.1K
Apr 03, 2025	1.50	1.55	1.48	1.51	86.16K
Apr 02, 2025	1.54	1.61	1.51	1.56	88.98K
Apr 01, 2025	1.54	1.62	1.50	1.50	175.78K
Mar 31, 2025	1.61	1.66	1.52	1.52	172.6K
Mar 28, 2025	1.64	1.67	1.60	1.64	85.25K
Mar 27, 2025	1.67	1.69	1.61	1.66	94.14K
Mar 26, 2025	1.69	1.70	1.60	1.64	116.5K
Mar 25, 2025	1.72	1.72	1.65	1.69	113.84K
Mar 24, 2025	1.80	1.89	1.71	1.74	180.06K
Mar 21, 2025	1.52	1.91	1.52	1.80	726.2K

Contact Details

Cambridge, MA 02142

United States

Website: https://immuneering.comContact: 617 500 8080

About Company

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Frequently Asked Questions

What is the current Immuneering Corporation (IMRX) stock price?

Immuneering Corporation (NASDAQ: IMRX) stock price is $1.27 in the last trading session. During the trading session, IMRX stock reached the peak price of $1.30 while $1.24 was the lowest point it dropped to. The percentage change in IMRX stock occurred in the recent session was 1.6% while the dollar amount for the price change in IMRX stock was $0.02.

IMRX's industry and sector of operation?

The NASDAQ listed IMRX is part of Biotechnology industry that operates in the broader Healthcare sector. Immuneering Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of IMRX?

Dr. Brett M. Hall Ph.D.
Chief Scientific Officer
Mr. Michael D. Bookman J.D.
Chief Legal Officer & Sec.
Ms. Paula George C.P.A.
Director of Accounting & Operations and Assistant Corporation Controller
Mr. Steve Bressler
Vice President & Head of Information Technology
Mr. Harold E. Brakewood
Chief Bus. Officer
Ms. Paula George CPA
Director of Accounting & Operations and Assistant Corporation Controller
Ms. Mallory Morales CPA
Vice President of Fin., Principal Financial & Accounting Officer and Treasurer
Ms. Leah R. Neufeld
Chief People Officer
Ms. Mallory Morales C.P.A.
Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer
Dr. Mohamedi Kagalwala M.B.A., Ph.D.
Head of Neuroscience Devel.
Dr. Scott Barrett M.D.
Chief Medical Officer
Dr. Peter King Ph.D.
Head of Discovery & Vice President
Dr. Rajaraman Krishnan Ph.D.
Head of Neuroscience Discovery
Dr. Andrew Lysaght Ph.D.
Vice President & Head of Bioinformatics
Dr. J.L. Ross Ph.D.
Vice President & Head of Neuroscience
Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D.
Co-Founder, Pres, Chief Executive Officer & Director
Dr. Praveen Nair Ph.D.
Head of Translational Pharmacology & Vice President

How IMRX did perform over past 52-week?

IMRX's closing price is 27% higher than its 52-week low of $1.00 where as its distance from 52-week high of $3.83 is -66.84%.

How many employees does IMRX have?

Number of IMRX employees currently stands at 66.

Link for IMRX official website?

Official Website of IMRX is: https://immuneering.com

How do I contact IMRX?

IMRX could be contacted at phone 617 500 8080 and can also be accessed through its website. IMRX operates from 245 Main Street, Cambridge, MA 02142, United States.

How many shares of IMRX are traded daily?

IMRX stock volume for the day was 60.73K shares. The average number of IMRX shares traded daily for last 3 months was 235.26K.

What is the market cap of IMRX currently?

The market value of IMRX currently stands at $45.58M with its latest stock price at $1.27 and 35.89M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

Home About Meet The Team Contact Us Privacy Policy Newsletter

News

Investing Crypto Market Business US Stocks

Useful Links

Screener Market Data Insider Transactions Upgrades & Downgrades 52 Week Highs & Lows Unusual Volume Dividend Calendar Earnings Calendar

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	66
Beta	-0.26
Sales or Revenue	$0.00
5Y Sales Change%	-1%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology